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Abstract
Purpose Paucity of reliable long-term data on the prognostic implications of the 2004 WHO bladder cancer classification 
system necessitates utilisation of both this and the 1973 grading systems. This study evaluated, in noninvasive (pTa) bladder 
tumours, the prognostic value of the 2004 system independently and in combination with the 1973 system while establishing 
concordance between tertiary centre uropathologists.
Methods We used a cohort of non-muscle invasive bladder cancer (NMIBC) patients diagnosed between 1991 and 93 where 
tumour features were gathered prospectively with detailed cystoscopic follow-up data recorded over 15 years. Initial grading 
was by one senior expert uropathologist (UP1) using the 1973 WHO classification alone. Subsequently, two other expert 
uropathologists (UP2 and UP3), blinded to the previous grading, re-evaluated the pathology slides and graded the tumours 
using both the 1973 and 2004 systems. Association between grade and recurrence/progression was analysed and the Cohen 
Kappa test assessed concordance between pathologists.
Results Of 370 new NMIBC, 229 were staged noninvasive (pTa). Recurrence rates were 46.2% and 50.0% for LGPUC 
(low-grade papillary urothelial carcinoma) and HGPUC (high-grade papillary urothelial carcinoma), respectively, while 
progression was seen in 3.9% and 10.0% of LGPUC and HGPUC, respectively. Concordance between uropathologists UP2 
and UP3 for the 2004 and 1973 systems was good (Kappa = 0.69) and fair (Kappa = 0.25), respectively.
Conclusions With good inter-observer concordance, the 2004 WHO classification system of noninvasive bladder tumours 
appears to accurately predict recurrence and progression risks. The combination of both grading systems to low-grade 
tumours allows further refinement of the natural history.
Keywords Bladder cancer · Non-muscle invasive bladder cancer (NMIBC) · WHO classification · ISUP classification · 
Prognosis · Long-term follow-up
Introduction
The management of patients with bladder cancer, in the 
absence of reliable biomedical markers, is dependant largely 
on the Histopathological interpretation of cellular appear-
ance. To this end, the WHO introduced the 1973 classi-
fication system [1]. To date, this forms the foundation of 
many clinical trials, nomograms, and risk calculators [2–4]. 
In non-muscle invasive bladder cancer (NMIBC), which 
accounts for up to 80% of new bladder cancers, the risk of 
recurrence can be as high as 80% and the risk of progression 
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to muscle invasive cancer can be up to 20%. The tumour 
grade forms a useful surrogate of tumour behaviour [3, 5].
Due to the apparent lack of reproducibility and accuracy 
of the 1973 classification system in part due to poor descrip-
tion of criteria for each grade [6], a new grading system was 
suggested 25 years later [7]—as this grading system was 
published in the 2004 edition of the “blue books” WHO 
classification of tumours, it became popularised as the 2004 
classification of urothelial carcinoma grading [8].
There is paucity of reliable long-term data on the prog-
nostic implications of the 2004 classification system and 
a reluctance of many clinicians to abandon a system that 
they are familiar with and on which much of the long-term 
prognostic studies are based. This has resulted in a recom-
mendation to utilise both systems, including by bodies like 
the EAU [9] and the UK Royal College of Pathologists [10].
Having previously published on the long-term follow-
up of Ta tumours using the 1973 classification [11, 12] 
in tumours during the era of trials that contributed to the 
EORTC risk tables, we designed this study to: (a) assess 
the predictive value of the 2004 classification system alone 
and in combination with the 1973 system in relation to 
recurrence and progression and (b) to assess concordance 
between pathologists using both grading systems.
Patients and methods
We accessed the archived histo-pathology slides for all new 
bladder tumour patients used in the previous study from our 
group [12]. Data pertaining to recurrence and progression 
had already been analysed previously from this cohort of 
patients with NMIBC. Our pathologists were blinded to the 
follow-up findings.
Three experienced uropathologists working in a univer-
sity hospital tertiary centre (with over 10 years experience 
each as specialist uropathologists) were involved in this 
study and evaluation of tumour histo-pathology. Uropatholo-
gist (UP1) who had reviewed the histo-pathology slides in 
the 1990s reviewed the slides once more and defined tumour 
grades using only the WHO 1973 classification system. 
The other two uropathologists (UP2 and UP3) were asked 
to independently classify tumours using the 1973 and the 
2004 classification systems to define pathological grade. The 
uropathologists involved in this study were not permitted to 
compare their grading results.
Tumour stage was defined using the TNM classification. 
Only tumours which had been accepted as being pTa by all 
three uropathologists were included in the analysis.
Using the 2004 classification system, for consistency in 
description, low- and high-grade Ta (noninvasive) tumours 
were called low-grade papillary urothelial carcinoma 
(LGPUC) and high-grade papillary urothelial carcinoma 
(HGPUC), respectively. Other descriptions were papilloma 
and papillary urothelial neoplasia of low malignant potential 
(PUNLMP).
Only patients with new tumours diagnosed between 1991 
and 1993 were included in the study. The database available 
included only patients with urothelial carcinoma. Exclu-
sion criteria for analysis were recurrent tumours, pTx, pT1, 
and pT2 tumours. The follow-up regime and intravesical 
chemotherapy employed were based on the guidelines of the 
time and all patients were discussed at a multi-disciplinary 
meeting, as published previously [12]. Follow-up flexible 
cystoscopy commenced at 3 months after primary treat-
ment which was either by transurethral resection of bladder 
tumour (TURBT) or biopsy and diathermy (B&D). This was 
followed by a flexible cystoscopy at 6-, 9-, and 12-month 
cystoscopy prior to annual follow-up for those remaining 
tumours free.
Recurrence was defined as a pathologically proven 
tumour. Progression was defined as a recurrence with a 
higher grade to what was noted at the initial diagnosis and/
or development of pT1 or pT2 disease. The pathology of 
the recurrent tumour was defined by UP1 who acted as the 
reference pathologist.
Data were analysed using the SPSS ver 16.0 software. 
Recurrence and progression-free survival were evaluated 
using Kaplan–Meier curves and the log-rank test. Concord-
ance between uropathologists was evaluated using the Cohen 
Kappa (κ). Accepted κ values for fair agreement (0.21–0.40), 
moderate agreement (0.41–0.60), and good agreement 
(0.61–0.8) were used [13].
Results
From a total of 508 patients with urothelial carcinoma, 
370 (72.8%) consecutive NMIBC patients were assessed, 
of whom there were 229 (61.9%) patients with pTa 
tumours—89 (38.9%), 109 (47.6%), and 31 (13.5%) were 
defined as Grades 1, 2, and 3, respectively, by UP1 using 
the 1973 classification system. Of these patients, 47 (23.7%) 
with G1 and G2 tumours were excluded from the analysis 
due to the finding of some possible lamina propria inva-
sion on review by any one of the three uropathologists. In 
the total NMIBC cohort, 80 (21.6%), 61 (16.5%) were cat-
egorised pT1 and pTx, respectively, by UP1, and, therefore, 
excluded from evaluation by the other two uropathologists.
Of the patients with pTa cancer included in the analy-
sis (n = 182), there were 115 male (63.2%) and 67 female 
(36.8%) patients with a mean age of 69.7 years (range: 
48.6–91.1) at the time of diagnosis. The median duration of 
surveillance was 92 months (3–174 months).
All 31 patients with Grade 3 pTa tumours were classed 
as high grade using the 2004 grading system by both 
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UP1 and UP2. Eight (25.8%) of these patients had cis 
in the initial histology. Of the Grade 3 pTa tumours, 21 
(67.7%) were small (< 3 cm) and 18 (58.1%) were single 
at presentation.
Of the 151 (Grade 1 or Grade 2) pTa patients, single 
and multiple tumours were found in 134 (88.7%) and 17 
(11.3%) patients, respectively. Small tumours (< 3 cm) and 
large tumours (≥ 3 cm) were found in 106 (70.2%) and 45 
(29.8%). A single post-TURBT instillation of mitomycin C 
was given following the initial TURBT in 11 (13.3%), 12 
(17.7%), and 3 (9.7%) G1pTa, G2pTa, and G3Ta patients, 
respectively; while a 6-week course of weekly mito-
mycin C was used in 3 (3.6%) G1Ta and 4 (5.9%) G2Ta 
patients. Intravesical BCG was used in 8 (25.8%) of the 
G3Ta patients and upon progression in 4 (5.9%) G2Ta and 
1 (1.2%) G1Ta patients.
Both Grade 1 and Grade 2 patients had a larger proportion 
of LGPUCs (Table 1). A small number of Grade 1 neoplasm 
cases were reclassified as PUNLMP using the WHO 2004 
classification system. HGPUC were only seen in a small 
proportion of those labelled as Grade 2 using the older clas-
sification system—8/68 (11.8%) and 11/68 (16.2%) patients 
who were initially classified as Grade 2 (1973 classification 
system) were labelled high grade by UP2 and UP3, respec-
tively, using the later classification system.
Using grade alone as predictor of recurrence, the 2004 
system revealed a trend of rising recurrence from PUNLMP 
through to HGPUC, a trend that the older classification sys-
tem failed to demonstrate (Table 2).
The risk of progression was proportionate to the tumour 
grade as determined by reclassification using the 2004 sys-
tem—the addition of the 1973 classification system to the 
2004 system (i.e., categorising as low-grade G1 and low-
grade G2) allowed further sub-stratification of the low-
grade tumours with a clear separation in risk of progression 
between the two sub-strata (Fig. 1). Inter-observer concord-
ance/agreement was deemed to be ‘good’ when using the 
two-tier 2004 classification system and, at best, ‘moderate’ 
with the three-tier 1973 classification system (Table 3).
Discussion
The WHO 1973 standard for classification and grading 
of bladder tumours is often considered a robust clinically 
proven, widely used, time-tested, and reasonably reproduc-
ible method for pathologic reporting, and is recommended 
with minor modifications—thus despite the introduction of 
the 2004 system, the EAU and UK Royal College of Pathol-
ogist guidelines (amongst others) recommend the use of both 
classification systems mainly to obtain long-term results—at 
least until long-term validation data of the 2004 classifica-
tion system are available [14]. The newer classification sys-
tem has been around for more than a decade and publications 
evaluating its longer term validity are somewhat scarce, to 
our knowledge, but nonetheless deemed reliable [9]. The 
2004 classification system is still being recommended to be 
used alongside the 1973 system as best practice, despite a 
recent (2016) update of the classification system [15] and 
some recent evidence in favour of the 1973 classification 
system in pT1 cancers [16]. It must be noted that the 2004 
system has not been used in any prognostic risk-models to 
date [9].
The combination of the two classification systems and 
its benefits is one of the aspects which we have explored in 
this study—whilst, to our knowledge, this is the first pro-
spectively maintained cohort of patients with long-term 
Table 1  WHO 1973 and 2004 
grading for tumours graded as 
G1, G2, and G3 by UP1
UP1 WHO 1973 UP2 WHO 1973 UP2 WHO 2004 UP3 WHO 1973 UP3 WHO 2004
G1 = 83 G1 = 58 Papilloma = 0 G1 = 39 Papilloma = 0
G2 = 25 PUNLMP = 6 G2 = 44 PUNLMP = 2
G3 = 0 LGPUC = 74 G3 = 0 LGPUC = 81
HGPUC = 0 HGPUC = 0
G2 = 68 G1 = 21 Papilloma = 0 G1 = 6 Papilloma = 0
G2 = 45 PUNLMP = 0 G2 = 62 PUNLMP = 0
G3 = 2 LGPUC = 60 G3 = 0 LGPUC = 57
HGPUC = 8 HGPUC = 11
G3 = 31 G3 = 31 HGPUC = 31 G3 = 31 HGPUC = 31
Table 2  Recurrence rate (risk of developing at least one recurrence 
through out the duration of follow-up)
Tumour grade Recurrence (%)
1973 Grade (grading by UP1)
 G1 50/83 (60.2)
 G2 34/68 (50.0)
2004 Grade (where both UP2 and UP3 concurred on the grade)
 PUNLMP 3/6 (50.0)
 LGPUC 41/85 (48.2)
 HGPUC 4/6 (66.7)
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follow-up being used to evaluate the new classification 
system, we also provide a unique demonstration of the 
value in combining the two systems. The low-grade G1 and 
low-grade G2 categories revealed some separation in the 
Kaplan–Meier curves. Despite a non-statistically significant 
difference (possibly consequent to a modest sample size), 
this combination offers an enhanced prognostic value—we, 
therefore, feel that this additional prognostic information, 
in the absence of reliable bio-markers, could help to better 
inform patients and select those suitable for adjuvant chemo 
or immunotherapy. The WHO 2004 classification system is 
not directly interchangeable with the WHO 1973 system. 
We observed a minority of cases previously termed Grade 1 
tumours that may represent PUNLMP, but, diagnostically, 
these are difficult to separate out with confidence. The 
remaining Grade 1 tumours would be classified as LGPUC 
using the new system [17]. While the majority of Grade 2 
tumours would be classified as LGPUC on review, there is 
a significant minority of Grade 2 tumours that would be re-
graded as HGPUC using the new system. Almost all nonin-
vasive Grade 3 neoplasms will be allocated to the HGPUC 
group using the new system [17].
Prediction of recurrence and progression
The recommendation by the Royal College of Pathologists is 
that PUNLMP is not used by UK pathologists as consistency 
in discriminating this entity from an LGPUC or Grade 1pTa 
Urothelial carcinoma is regarded as exceptionally difficult 
[10]. It is quite possible that very experienced uropatholo-
gists might be better at separating these, but this skill is not 
ubiquitous. In addition, it can also be confusing regarding 
management as the long-term natural history of PUNLMP 
is un-known and essentially most clinicians will follow-up 
as G1pTa. From our study, our expert uropathologists did 
not categorise many low grade (from the 1973 system) into 
PUNLMP and in the ones, that were given this label, the 
risk of recurrence appeared not dissimilar to the LGPUC 
category. The observation of a lower proportion of PUN-
LMP was equally reported by others [18]. More importantly, 
the risk of progression was indeed negligible in the PUN-
LMP category. This appeared to be in-keeping with findings 
from Holmang et al. [19, 20], who, on evaluating a cohort 
120.00100.0080.0060.0040.0020.000.00
Time to progression (mths)
1.0
0.8
0.6
0.4
0.2
0.0
Cu
m
 S
ur
vi
va
l
PUNLMP-censored
LG2-censored
LG1-censored
HG-censored
PUNLMP
LG2
LG1
HG
grade
Time (mths) 0 20 40 60 80 100 120
No. at risk HG 6 5 4 4 3 3 3
LG1 32 30 27 23 20 16 10
LG2 53 47 39 28 22 19 13
PUNLMP 6 6 6 6 5 4 4
Fig. 1  Progression-free survival in patients initially classified as G1 or G2 by UP1 (HG High-Grade, LG1 Low-Grade-Grade 1, LG2 Low-Grade-
Grade 2, PUNLMP papillary urotheliam neoplasia of low malignant potential)
Table 3  Concordance/agreement between uropathologists
Pathologists Kappa (κ), p value, agreement
1973 WHO classification system
 UP1 vs UP2 0.417, < 0.001, moderate
 UP1 vs UP3 0.330, < 0.001, fair
 UP2 vs UP3 0.253, 0.001, fair
2004 WHO classification system
 UP2 vs UP3 0.693, < 0.001, good
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of 95 patients with PUNLMP, found recurrences in 35% and 
no progressions over 5 years of follow-up (supporting the 
notion of difficulty in making this diagnosis and separating 
from LGPUC). Conversely, patients with LGPUC had recur-
rence and progression rates of 71% and 4%, respectively. 
Similar findings were reported by others who also evaluated 
the relationship between LGPUC and some molecular mark-
ers [21–23]. However, there are varying reports from other 
authors, with progression observed even in PUNLMP (range 
0–8%) [24]. In our opinion, this heterogeneity of recurrence 
rates (and even progression) is not necessarily the result of 
heterogeneity in tumour behaviour, rather more likely the 
effect of differing surgical quality [25]. The improved quality 
of initial tumour resections has now produced a significant 
reduction in recurrence rates and, consequently, will make 
comparisons between contemporary and historical series dif-
ficult, if not untenable.
Using grade alone as a predictor of recurrence, the 2004 
system revealed a trend of rising recurrence from PUNLMP 
through to HGPUC, a trend that the older classification sys-
tem failed to demonstrate (Table 3). Risk tables using the 
1973 classification system [3] had consistently showed that 
the grade was a better predictor of progression compared to 
recurrence, which is better determined by multiplicity and 
size of the tumour. Equally, the 2004 system appeared to be 
more representative of the tumour natural history in rela-
tion to progression. Cao and colleagues [26] demonstrated 
that the 2004 classification system predicted recurrence and 
progression better than the 1973 system, particularly in non-
invasive tumours, while Otto et al. [27] and Pelluchi et al. 
[16] revealed that the 1973 classification system was better 
in pT1 cancers regarding the prediction of progression. In 
addition, Burger et al. revealed that the 2004 system was 
more accurate in predicting recurrence in patients with regu-
lar onset bladder cancer compared to those with the early 
onset bladder cancer (> 45 years of age) [28].
Inter‑observer variability
We ensured that the three pathologists involved in the study 
did not confer on the grading ascribed to a tumour. All G3 
tumours became HGPUC with the 2004 classification sys-
tem, i.e., there was no doubt between all three uropatholo-
gists regarding the categorisation. Our uropathologists 
appeared to have more concordance when using the 2004 
system compared with the 1973 one, i.e., there appears to 
be lesser inter-observer variability with th“e 2004 system. 
It is well accepted within Pathological literature that a two-
tier grading system is easier to use and provides less inter-
observer variability than a three-tier system where there is 
a tendency to “drift to place cases in the middle group”. 
The recent EAU guidelines conclude, “The published com-
parisons have not clearly confirmed that the WHO 2004 
classification system provided better reproducibility than the 
1973 system” [9]. In Germany, May and colleagues [18], 
from a retrospective review of 200 patients, confirmed a 
better concordance between uropathologists when using the 
2004 classification system as compared to the 1973 one—
Kappa (κ) value was up to 0.52 in a comparison between 
two pathologists probably for similar reasons to ours. An 
analysis of a small Australian patient cohort also revealed 
a similar inter-observer variability as our recent analysis 
[29]. Mangrud and colleagues [30], analysing 193 bladder 
tumours with a median follow-up of 75 months, revealed that 
a Kappa value of 0.68 for inter-observer agreement in Grade 
1 and 2 tumours (using the 1973 classification system) and 
inter-observer agreement for the 2004 system was 0.7, con-
cluding that neither system was prognostically superior than 
the other. To negate this inter-observer variability and the 
potential change in clinical management [31], certainly the 
Urology community and much of the practice in UK cancer 
centres, like ours, rely on consensus of opinion of at least 
two expert pathologists in most bladder cancer evaluations.
High throughput with next-generation sequencing has 
now allowed us to better understand the genomic patterns 
in bladder cancer [32] and potentially allow for targeted per-
sonalised treatment ̄—however, there is an observed hetero-
geneity in the association between molecular profiles and 
clinical behaviour [33]. Burger et al. performed a prospective 
evaluation of the association between recurrence and pro-
gression (over 3 years) against the 1973 classification sys-
tem, 2004 system, and FGFR mutation status in patients with 
NMIBC. The authors concluded that both grading systems 
provided valuable prognostic information, particularly in the 
ability to predict progression. FGFR mutation appeared to 
act as an adjunct to the prognostication in only High-Grade 
cancer [34]. Intuitively, reliable biomolecular markers (when 
available) are likely to not only improve prognostication in 
the future, but also provide a more uniform platform for 
consistent reporting and, therefore, molecular pathology 
and bio-markers should be the way forward in introducing 
objectivity, consistency, and reproducibility to prognostica-
tion in NMIBC [33]. In the future, with the reduced cost 
and potential universally accessible genomic analysis using 
next-generation sequencing, molecular evaluation should be 
an adjunct to (and not a replacement of) histo-pathological 
assessment [35], especially as some early data already allude 
to, for example, proliferative differences based on molecular 
markers [23].
Although the number of patients in our study appears 
to be at par, if not larger, and the follow-up appears to be 
longer than several other publications, the cohort is still 
quite modest. It would appear that most other publica-
tions also referred to the sample size as tumour number as 
opposed to number of patients [18, 30]. The modest size 
of our cohort also precluded the simultaneous evaluation 
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of recurrence/progression risk by stratifying to tumour fea-
tures (number and size)—the emphasis of this work being 
the value of the WHO grading systems, not dissimilar to 
the approach of other authors [18, 28]. Combination of raw 
data from the other groups may help in achieving a much 
larger cohort to validate our observations. T1 tumours 
were not included as the outcomes from the 1990s are 
unlikely to mirror the current approach, especially in light 
of the more ubiquitous recent practice of early re-TURBT 
in this group of patients—a practice that was not routine in 
earlier series. Grade 3 tumours would have similar impli-
cations. While we did have information about presence of 
cis in the initial histology, other prognostically relevant 
features in current pathology reports (such as lympho-
vascular invasion and micropapillary appearance), were 
not discernible for this cohort. Long-term outcomes from 
this cohort may also not necessarily represent findings in 
contemporary practice, where there is improved quality 
of the initial surgery, increased usage of immediate post-
operative chemotherapy, and adjuvant chemo/immunother-
apy. However, this cohort was chosen for its proximity to 
those in the era of the trials that were used in the develop-
ment of the EORTC risk tables; the use of post-operative 
instillation of chemotherapy was also part of the MRC trial 
[2]; and we had reliable prospective long-term follow-up. 
The difference in progression risk between LG-G1 and 
LG-G2 noted in this study is unlikely to have been altered 
even if there was a hypothetical wider use of a single post-
operative chemotherapy instillation as the further meta-
analysis of previous clinical trial data demonstrated that 
the tumour grade did not affect response to the immediate 
post-TURBT intravesical chemotherapy [36].
Conclusion
From this cohort of NMIBC with prospective long-term 
follow-up, the 2004 WHO classification system appears to 
better predict the risk of progression and has lower inter-
observer variability. Augmenting this grading system with 
the 1973 WHO classification system appears to improve 
prognostic value. We recommend further assessment with 
a larger multi-centre cohort of contemporary patients with 
long-term follow-up.
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